Search Within

Lorenzo Falchi

Formats
  1. Meeting Abstract (98)
  2. Journal Article (23)
  3. Research Letter (6)
  4. Review (5)
  5. Correspondence (2)
  6. Editorial (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (136)
  2. Hematologic Malignancies, Division of (136)
  3. Center for Hematologic Malignancies (88)
  4. Hematology-Oncology Fellows (81)
  5. Lymphoma (78)
  6. Weinberg Fellows (58)

More Groups

People
  1. Gilles Salles (66)
  2. Andrew Zelenetz (64)
  3. Maria Palomba (63)
  4. Anita Kumar (61)
  5. Ariela Noy (57)
  6. Alison Moskowitz (54)

More People

Years
  1. 2025 (10)
  2. 2024 (40)
  3. 2023 (43)
  4. 2022 (23)
  5. 2021 (14)
  6. 2020 (6)
Publications
  1. Blood (67)
  2. Journal of Clinical Oncology (11)
  3. Hematological Oncology (9)
  4. Blood Advances (5)
  5. British Journal of Haematology (5)
  6. Clinical Lymphoma, Myeloma and Leukemia (5)

More Publications

Publishers
  1. American Society of Hematology (72)
  2. American Society of Clinical Oncology (11)
  3. Wiley Blackwell (9)
  4. Elsevier Inc. (8)
  5. John Wiley & Sons (6)
  6. Taylor & Francis Group (5)

More Publishers

Results (136)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas
    Journal Article

    Ghione, P.; Bantilan, K. S.; Joffe, E.; Palomba, M. L.; Noy, A.; Caron, P.; Hamlin, P.; Kumar, A.; Matasar, M.; Owens, C.; more...
    Blood Neoplasia (2024)

    Fulltext@MSK | Save
  • Rituximab plus /- ibrutinib as first line therapy for marginal zone lymphoma
    Meeting Abstract

    Noy, A.; Thet, W. S.; Vemuri, S.; Seshan, V.; Batlevi, C. L.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Habermann, T. M.; Hamlin, P. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Two decade single institution experience highlights rare survivors with relapsed or refractory Burkitt lymphoma
    Meeting Abstract

    Molla, R.; Berman, E.; Caron, P.; Donnelly, G.; Falchi, L.; Hamlin, P. A.; Horwitz, S.; Intlekofer, A. M.; Johnson, W. T.; Jurcic, J. G.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Sequential R-CHOP/(R)-ICE and dose-adjusted EPOCH-R are both appropriate frontline treatments for newly diagnosed primary mediastinal B-cell lymphoma: Results of a retrospective analysis
    Meeting Abstract

    Bantilan, K. S.; Luttwak, E.; Moskowitz, C. H.; Matasar, M.; Straus, D. J.; Portlock, C. S.; Moskowitz, A.; Noy, A.; Palomba, M. L.; Horwitz, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Angioimmunoblastic versus non-angioimmunoblastic nodal T-follicular helper cell lymphomas: Single center retrospective analysis on 208 cases
    Meeting Abstract

    Sordi, B.; Eren, O. C.; Ganesan, N.; Iyengar, V.; Stuver, R.; Johnson, W. T.; Moskowitz, A.; Ghione, P.; Galasso, N.; Casper, E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A prospective geriatric assessment (GA) study predicting toxicities in older adults (OA) with non-Hodgkin Lymphoma (NHL): Timed up and go test (TUG) time emerges as a functional vital sign
    Meeting Abstract

    Torka, P.; Drill, E.; Ganesan, N.; Truong, R.; Qiu, A.; Amador, W. R.; Oliveros, M.; Boardman, A. P.; Caron, P.; David, K. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab and involved site radiation therapy alone as an alternative to transplant in patients with localized failure following chemotherapy for Hodgkin Lymphoma: A prospective multicenter phase II study
    Meeting Abstract

    Dreyfuss, A.; Ganesan, N.; Alencar, A. J.; Boardman, A. P.; Caron, P.; Chang, T.; Davey, T.; David, K. A.; Dogan, A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Improved outcomes for primary refractory classical Hodgkin Lymphoma: A retrospective analysis
    Meeting Abstract

    Santarosa, A. M.; Ganesan, N.; Chang, T.; Hannigan, K.; Casper, E.; Shah, G. L.; Boardman, A. P.; Caron, P.; David, K. A.; Dogan, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Comparative real-world outcomes of commercial CD19-directed CAR T-cell therapies in large B-cell lymphoma
    Meeting Abstract

    Deschè‚nes-Simard, X.; Bromberg, M.; Devlin, S. M.; Katz, O. B.; Ip, A.; Marcus, R.; Avigdor, A.; Ballweg, A.; Rabinovich, E.; Alhomoud, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • BP43131, a phase 1 dose escalation study: CD19 targeted CD28 costimulatory agonist (RO7443904) combined with glofitamab shows promising efficacy in patients with relapsed/refractory aggressive B-NHL
    Meeting Abstract

    Dickinson, M. J.; Hutchings, M.; Morschhauser, F.; Carlo-Stella, C.; Falchi, L.; Caimi, P. F.; Dimier, N.; Smith, L.; Whayman, M.; Sam, J.; more...
    Blood (2024)

    Fulltext@MSK | Save